Diets in Oncology
Evidence-based dietary patterns relevant to cancer prevention and care — what research actually supports, without miracle claims. Diet supports treatment; it never replaces it.
Grapefruit and anticancer drugs
Grapefruit is an ordinary fruit, and for that very reason it is often left out of conversations about medication. Its furanocoumarins inhibit CYP3A4, the enzyme that metabolises many anticancer drugs [1]. The effect is not one-directional: with nilotinib, grapefruit juice increased the area under the curve by 29% and peak serum concentration by 60%; with sunitinib it increased bioavailability; whereas with etoposide bioavailability FELL from about 73% to 52%, corresponding to a 26% reduction in exposure [1]. With imatinib, a risk of raised plasma levels and organ toxicity has been described [1]. The same applies to related fruits: Seville orange, pomelo and lime [1].
Read more — evidence, cautions, sources
WHY THIS IS A TOPIC AT ALL
A supplement suggests risk; a fruit does not. A patient who honestly lists every preparation they take will usually not mention the daily glass of grapefruit juice. Yet this is one of the best-documented food-drug interactions in all of pharmacology, and in oncology it concerns drugs taken by mouth, daily, for many months.
MECHANISM: The furanocoumarins present in grapefruit inhibit the cytochrome P450 enzyme CYP3A4 [1]. CYP3A4 metabolises a great many anticancer drugs, so inhibiting it changes how much drug reaches the bloodstream. The key point is that this change happens OUTSIDE dosing control: the patient takes the prescribed dose, while the body behaves as if it had received a different one.
WHAT HAS BEEN MEASURED — THE NUMBERS:
- NILOTINIB: in a clinical trial, combination with grapefruit juice increased the area under the concentration curve by 29% and peak serum concentration by 60% [1];
- SUNITINIB: a clinical trial observed increased bioavailability after grapefruit juice exposure [1];
- IMATINIB: a clinical review indicates the juice may raise plasma levels by inhibiting CYP3A4 and trigger organ toxicity [1];
- ETOPOSIDE: the OPPOSITE direction — after grapefruit juice pretreatment, bioavailability fell from about 73% to 52%, corresponding to a 26% reduction in area under the curve [1].
WHY THE DIRECTION CAN REVERSE
This is the most commonly misunderstood part. The popular belief is that grapefruit makes drugs stronger. With etoposide the opposite occurred, and that situation is the more dangerous one, because lower exposure to an anticancer drug means weaker treatment than planned and produces no symptom by which it could be noticed. Toxicity is visible; loss of efficacy is not.
NOT ONLY GRAPEFRUIT
Alongside grapefruit, NCI names fruits with comparable interaction potential: Seville orange (an ingredient of marmalades and some liqueurs), pomelo and lime [1].
WHAT THIS ENTRY DOES NOT SAY
It neither recommends nor discourages eating grapefruit for any individual and gives no safe quantities — NCI publishes interaction tables but makes no explicit recommendation about avoiding grapefruit during cancer therapy [1], and the answer depends on the specific drug a patient is taking. Most intravenous chemotherapy is unaffected; the issue concerns chiefly oral drugs metabolised by CYP3A4.
WHAT TO TELL THE TREATING TEAM
About regular consumption of grapefruit juice or these fruits — ideally before oral treatment begins. The question to ask the doctor or clinical pharmacist is simply: is my drug metabolised by CYP3A4. That single question settles the matter, and the answer is in the summary of product characteristics.
Sources
- [1] National Cancer Institute — Cancer Therapy Interactions With Foods and Dietary Supplements (PDQ), Health Professional Version (furanokumaryny i CYP3A4; nilotynib AUC +29% i Cmax +60%; sunitynib; imatynib; etopozyd 73% do 52%, AUC -26%; pomarancza sewilska, pomelo, limonka): cancer.gov ↗
This page is educational — it is not medical advice and does not replace consultation with an oncologist. Diagnostic and treatment decisions are made solely by specialist physicians.